Skip to content

Ultrasound Guided Femoral Nerve Block

Comparison of Ultrasound Guided Femoral Nerve Blockade and Standard Parenteral Opioid Pain Management Alone in Patients With Hip Fracture in the Emergency Department

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02381717
Enrollment
44
Registered
2015-03-06
Start date
2015-08-01
Completion date
2025-12-01
Last updated
2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Keywords

ultrasound, bupivacaine, femoral nerve block, pain reduction

Brief summary

The goal of the study is to evaluate whether pain control achieved by Ultrasound Guided Femoral Nerve Blockade (USFNB) is equal in efficacy to standard pain management practice of parenteral injection of opioid pain medication in patients presenting to the emergency department (ED) with hip fracture.

Detailed description

In this proposed protocol the investigators will conduct a prospective, randomized control trial comparing the efficacy of Ultrasound Guided Femoral Nerve Blockade (USFNB) versus the standard of care pain management by parenteral injection of opioid pain medication of patients presenting with hip fracture at the BIDMC ED. We hypothesize that USNFB approach will be non-inferior in achieving pain control (efficacy) and superior in the total dose of opioids (lower amount) as compared to the standard protocol. The enrolled population will be randomized 1:1 using a simple balanced randomization scheme. Participants will be surveyed six times 6 times on a Visual Analog Scale (VAS)\* on their pain intensity reduction over 4 hours. Physicians performing the block will be surveyed promptly following the procedure regarding difficulty performing the block and its efficacy. Specific Aim #1: The investigators hypothesize that in patients presenting to the ED with hip fracture, USFNB will demonstrate equal efficacy in pain relief with fewer side effects when compared to conventional parenteral opioid therapy. The investigators evaluate this hypothesis by monitoring Visual Analogue Scales (VAS) in patients receiving either USGFNB or opioid therapy over the first 4 hours of observation. The side effects will be noted during the same interval of time. Specific Aim #2: The investigators hypothesize that in patients presenting to the ED with hip fracture, USFNB will reduce the amount of narcotic used to control pain. The investigators will evaluate this by studying narcotic use over the first 4 hours of evaluation.

Interventions

OTHERultra-sound guide

Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound

DRUGbupivacaine
DRUGmorphine

Sponsors

Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 101 Years
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years of age presenting to the ED with radiographically established intra-, extracapsular hip fracture, able to consent and participate in the study and who have moderate to severe pain (numerical pain score \>= 31) at the time of enrollment.

Exclusion criteria

* Patients with a previous history of hypersensitivity to local anesthetics, * Patients who have signs of a local infection at the site of planned needle placement. * INR \> 1.4NOAC use within 48 hours * Prophylactic Low-Molecular Weight Heparin (LMWH) within 12 hours * Therapeutic LMWH within 24 hours * Prophylactic Unfractionated Heparin (5000 Units BID or TID) within 6 hours

Design outcomes

Primary

MeasureTime frameDescription
pain intensity reduction4 hours after initiation of study proceduureEvaluation of pain severity and relief will be assessed utilizing a Visual Analog Scale (VAS)

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBeatrice Hoffmann, MD PhD

Beth Israel Deaconess Medical

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026